All News

What constitutes comprehensive cancer care? One interpretation, by the National Cancer Institute (NCI), defines it as a commitment to exploring the basic science and clinical care of patients with cancer. Cancer centers designated by the NCI as

SEATTLE-Xcyte Therapies is testing in preclinical studies the feasibility of a new technology that would take T cells from patients with B-cell chronic lymphocytic leukemia (B-CLL) and spur them into action with key antibodies, with the goal of reinfusing them into the patient ready to fight B-cell tumors. Mark L. Bonyhadi, PhD, of Xcyte Therapies in Seattle, Washington, reported that the company’s Xcellerate technology "produces activated T cells that can interact with leukemic B cells and alter their behavior in vitro. We hope this will be followed by apoptosis or clearance of B cells in B-CLL patients."

ROCHESTER, Minnesota-More than half of follicular non-Hodgkin’s lymphoma (NHL) patients who progress after rituximab (Rituxan) treatment respond to the experimental drug ibritumomab tiuxetan (Zevalin), according to a multicenter clinical trial. Although most of the study’s 54 patients had only partial remissions after treatment with ibritumomab tiuxetan, their response continued for at least 8 months. In some cases, remissions have lasted up to 2 years.

NEW YORK-Short-term, intensive multiagent chemotherapy without high-dose methotrexate produces excellent outcomes in children with advanced non-lymphoblastic non-Hodgkin’s lymphoma, according to a Children’s Cancer Group (CCG) study. The estimated 5-year event-free survival (EFS) was 77% and the overall survival rate was 80% for the 39 patients enrolled in the pilot study, according to lead researcher Mitchell S. Cairo, MD, director of Pediatric Blood and Marrow Transplantation at Columbia University, New York.

STANFORD, California-Seventy percent of low-grade and transformed low-grade non-Hodgkin’s lymphoma (NHL) patients respond to the drug iodine I 131 tositumomab (Bexxar) even though progressing after rituximab (Rituxan). A study of 40 patients who had previously failed to respond or progressed on rituximab, also showed that 40% had a complete response or remission after treatment with iodine I 131 tositumomab.

ROCHESTER, Minnesota-A phase-III clinical trial has shown that 73% of B-cell non-Hodgkin’s lymphoma (NHL) patients respond to the radioimmunotherapy ibritumomab tiuxetan (Zevalin) vs 47% for rituximab (Rituxan). The study concluded that ibritumomab tiuxetan (Zevalin) is not only safe and effective, but the objective response rates achieved with it are statistically superior to those achieved with rituximab alone.

BIRMINGHAM, Alabama-Idiopathic thrombocytopenic purpura (ITP) may respond to rituximab (Rituxan) monoclonal antibody treatment, even in steroid-refractory patients, investigators reported in a poster presentation.

AMSTERDAM-Adding granulocyte colony-stimulating factor (G-CSF) to rituximab may improve response duration and increase the proportion of complete responses in patients with relapsed B-cell non-Hodgkin’s lymphoma (NHL). "Although the overall response rate seems comparable to data reported for rituximab monotherapy, the complete response rate is higher, and remission duration in this pilot phase-II study is remarkably long," Lizette E. van der Kolk, MD, reported in a poster presentation. Dr. van der Kolk is a member of the Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.

BUFFALO-Combining rituximab (Rituxan) with fludarabine (Fludara) for low-grade or follicular B-cell lymphomas may be as effective as but less toxic than rituximab plus CHOP (cyclophosphamide, doxorubicin, Oncovin [vincristine], prednisone). Phase II trial data supporting this assertion were presented.

WASHINGTON-What a difference a year makes. Cigarette smoking dropped significantly among middle school and high school students between 1999 and 2000, according to a new federally funded report. For example, the percentage of high school seniors who had smoked at least once in the month prior to being surveyed fell from 34.6% to 31.4% (Figure). Those 12th graders who smoked a half pack of cigarettes or more each day declined from 13.2% to 11.3%.

ATLANTA-Parecoxib, the first injectable COX-2 inhibitor, demonstrated impressive analgesic efficacy in postsurgical patients, according to a study presented at the 19th Annual Scientific Meeting of the American Pain Society (APS).

NEW YORK-"Use it or lose it," exercise buffs like to say, and the dictum is just as true for cancer patients, according to physical therapist Eileen Donovan, PT, MEd, manager of rehabilitation services at the University of Texas M.D. Anderson Cancer Center. Ms. Donovan discussed the topic during a Cancer Care teleconference.

SAN FRANCISCO-Administering highly active antiretroviral therapy (HAART) to HIV-positive patients during and after treatment for non-Hodgkin’s lymphoma (NHL) can significantly reduce the risk of NHL relapse and death.

STANFORD, California-A recombinant idiotype protein vaccine for treatment of non-Hodgkin’s lymphoma (NHL) induced both cellular and anti-idiotype tumor-specific immunity in phase-I/II trials and has now progressed to phase-III studies, reported John Timmerman, MD, research fellow, Division of Oncology, Stanford University Medical Center, Stanford, California.

WASHINGTON-Medicare will soon cover or expand its coverage of the use of positron emission tomography (PET) for the primary diagnosis, staging, or restaging of six types of cancer. The Health Care Financing Administration (HCFA) said it would announce an effective coverage date shortly.

SAN ANTONIO-Women with metastatic breast cancer who experience disease progression on trastuzumab (Herceptin) may benefit from continued treatment with the antibody, according to results of a crossover study presented by Debu Tripathy, MD, associate clinical professor of medicine, University of California, San Francisco, School of Medicine. Moreover, trastuzumab cardiotox-icity was only 2.2% among long-term users.

BALTIMORE-The B-cell directed monoclonal antibody rituximab (Rituxan) can produce durable complete remissions without the need for maintenance therapy in patients with cold agglutinin autoimmune hemolytic anemia (AIHA) and might also represent a treatment option in warm agglutinin AIHA, according to Edward Lee, MD. Dr. Lee is director of hematology and medical oncology at Sinai Hospital in Baltimore, and Director of the Bone Marrow Transplantation Program.

BOSTON-An experimental mixed-beam radiation technique can reduce the total radiation dose required by a factor of two in simple cancer cases, Michelle M. Svatos, PhD, reported at the American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting.

SAN FRANCISCO-Advances in gene therapy, cancer vaccines, and a variety of new antibody therapies for hematologic malignancies were the focus of a satellite symposium to the 42nd Annual Meeting of the American Society of Hematology titled Scientific and Technical Innovations in Biology: Initiating Advances in Therapeutic Approaches to Hematological Malignancies. The program was sponsored by Fox Chase Cancer Center through an unrestricted educational grant from Genentech BioOncology and IDEC Pharmaceuticals.

SOUTH SAN FRANCISCO-A new study reveals that patients who develop HAMA (human antibodies to the murine antibody) after treatment with iodine I 131 tositumomab (Bexxar) do not develop cross-reactive antibodies or immune reactions that would interfere with later treatment with rituximab (Rituxan).

HUDDINGE, SWEDEN-Two cycles of rituximab (Rituxan) are effective and well tolerated in patients with symptomatic previously untreated or first-relapse low-grade lymphomas, reported Eva Kimby, MD. Speaking on behalf of the Nordic Lymphoma Group, Dr. Kimby, who is in the Department of Medicine at Huddinge Hospital, in Huddinge, Sweden, said that early data suggest that the effect of rituximab might be augmented by interferon-alfa-2a (IFN). This phase-II study included researchers from Sweden, Norway, Denmark, and Finland.

SAN FRANCISCO-Umbilical cord blood transplants provide new hope for children with leukemia and genetic diseases requiring transplantation, Joanne Kurtzberg, MD, said at the 42nd Annual Meeting of the American Society of Hematology (ASH). She reported that 53% of pediatric patients treated with cord blood transplant at Duke University are surviving.

HOUSTON-Adding rituximab (Rituxan) to standard chemotherapy increased complete remission (CR) rates for chronic lymphocytic leukemia (CLL) and reduced the number of bone marrow cells expressing the CLL-associated cell-surface markers CD5 and CD19, according to Michael J. Keating, MD. "Fludarabine, cyclophosphamide, and rituximab (FCR) is the most active regimen explored by our group in previously untreated CLL, and the toxicity profile is similar to that seen with FC alone," said Dr. Keating, professor of leukemia developmental research at the University of Texas M. D. Anderson Cancer Center in Houston.

LYON, France-In one of the most eagerly awaited presentations at the 42nd Annual Meeting of the American Society of Hematology, Bertrand Coiffier, MD, predicted that the combination of rituximab (Rituxan) plus CHOP "may be the new standard for treatment of aggressive B-cell lymphomas in elderly patients." Head of hematology at Hospices Civilese de Lyon, Lyon, France, Dr. Coiffier presented an interim analysis of results from a European phase III trial of rituximab plus CHOP (cyclophosphamide, doxorubicin, Oncovin [vincristine], prednisone) in elderly patients with diffuse large B-cell lymphomas (DLBCL).

CHICAGO-Intensity modulated radiation therapy (IMRT) offers dramatic advantages for selected pediatric patients, such as those with sarcomas of the chest, abdomen, or pelvis, as well as children with tumors of the head and neck or brain, said Suzanne Wolden, MD, a radiation oncologist at Memorial Sloan-Kettering Cancer Center

SAN FRANCISCO-Iodine I 131 tositumomab (Bexxar) attains complete remission in more than one third of non-Hodgkin’s lymphoma (NHL) patients, and these responses can last several years, according to a 10-year study.

BOSTON-Gene expression profiling may help predict survival outcomes for patients with diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy, according to a study reported by Margaret Shipp, MD, director of the Lymphoma Program at Dana-Farber Cancer Institute in Boston. In the study, gene expression profiling was able for the first time to identify curable and noncurable lymphomas from a pool of intermediate-risk patients.

SAN FRANCISCO-Interim results of a trial of the combination of rituximab (Rituxan) and fludarabine (Fludara), a novel approach for the treatment of low-grade or follicular B-cell lymphoma, suggest excellent antitumor activity. Rituximab, an anti-CD20 monoclonal antibody, is the only approved monoclonal antibody therapy for refractory or relapsed low-grade or follicular non-Hodgkin’s lymphoma (NHL).

SAN FRANCISCO-The anemia drug darbepoetin alfa (ARANESP) effectively alleviates anemia, boosting hemoglobin counts and reducing the need for red blood cell transfusions, according to the results of two separate studies.

NEW YORK-Low doses of arsenic trioxide (ATO) given by intravenous injection are highly effective at inducing remission in patients with relapsed acute promyelocytic leukemia (APL) and should be tested in patients with newly diagnosed disease. These results and recommendation were based on research conducted at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York.